Location History:
- Leuven, BE (2017)
- Westmalle, BE (2017 - 2019)
Company Filing History:
7 out of 345 
7 out of 7 Years Active: 2017-2024
Title: Inventor Berten Ceulemens: Pioneering Treatments for Dravet Syndrome
Introduction
Berten Ceulemens is an innovative inventor based in Westmalle, Belgium, known for his significant contributions to medical research and treatments. With a remarkable portfolio of seven patents, Ceulemens has focused his work on addressing complex medical conditions, particularly in the realm of pediatric health.
Latest Patents
Among his latest patents, Ceulemens has developed a groundbreaking method for the treatment of Dravet Syndrome, a severe form of epilepsy that primarily affects children under the age of 18. His innovative methodology involves the administration of an effective dose of fenfluramine or its pharmaceutically acceptable salt. This treatment has shown promise, particularly at doses ranging from about 0.5 to about 0.01 mg/kg/day, providing hope to families dealing with this challenging condition.
Career Highlights
Ceulemens’ career has been marked by his dedication to medical advancements and innovative solutions to health problems. His patents reflect his commitment to improving the lives of children suffering from Dravet Syndrome and similar conditions. His work in this area demonstrates both expertise and compassion, as he seeks to provide effective treatments for vulnerable populations.
Collaborations
Throughout his career, Berten Ceulemens has collaborated with esteemed institutions, including Katholieke Universiteit Leuven and University Hospital Antwerp. These partnerships have allowed him to work alongside other experts in the field, such as his colleague Lieven Lagae, further enhancing the impact of his inventions.
Conclusion
Berten Ceulemens stands out as a dedicated inventor whose work has the potential to transform the landscape of treatment for Dravet Syndrome. Through his innovative methodologies and collaboration with leading research institutions, he continues to contribute significantly to the medical community, providing hope to families and influencing future research in pediatric epilepsy.